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Abstract
Background: Platinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian
cancer (OC). This randomized phase II study was undertaken in order to compare the combination of carboplatin
and pegylated liposomal doxorubicin (LD) with carboplatin and paclitaxel (CP) in this setting.
Methods: Patients with histologically confirmed recurrent OC, at the time of or more than 6 months after
platinum-based chemotherapy, were randomized to six cycles of CP (carboplatin AUC5 + paclitaxel 175 mg/m
2,
d1q21) or CLD (carboplatin AUC5 + pegylated LD 45 mg/m
2, d1q28).
Results: A total of 189 eligible patients (CP 96, CLD 93), with a median age of 63 years, median Performance
Status (PS) 0 and a median platinum free interval (PFI) of 16.5 months, entered the study. Discontinuation due to
toxicity was higher in the CP patients (13.5% versus 3%, P = 0.016). The overall response rate was similar: CP 58%
versus CLD 51%, P = 0.309 (Complete Response; CR 34% versus 23%) and there was no statistical difference in
time-to-progression (TTP) or overall survival (OS; TTP 10.8 months CP versus 11.8 CLD, P = 0.904; OS 29.4 months
CP versus 24.7 CLD, P = 0.454). No toxic deaths were recorded. Neutropenia was the most commonly seen severe
toxicity (CP 30% versus CLD 35%). More frequent in CLD were severe thrombocytopenia (11% versus 2%, P =
0.016), skin toxicity and Palmar-plantar erythrodysesthesia (PPE) grade 1-2 (38% versus 9%, P< 0.001), while grade 3
neurotoxicity and alopecia were higher in CP (7% versus 0%, P = 0.029, 20% versus 5%, P = 0.003). PS and PFI were
independent prognostic factors for TTP and OS.
Conclusions: The combination of pegylated LD with carboplatin is effective, showing less neurotoxicity and
alopecia than paclitaxel-carboplatin. It thus warrants a further phase III evaluation as an alternative treatment
option for platinum-sensitive OC patients.
Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12609000436279
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Ovarian cancer (OC) remains the leading cause of death
due to gynaecological malignancies [1]. The standard
first-line treatment is a platinum-paclitaxel combination,
achieving complete response rates of up to 50%. How-
ever, despite progress in first-line therapy, more than
60% of patients relapse and die from chemoresistant dis-
ease [2-4]. Therefore, the majority of patients will
become candidates for second-line treatment. It is gen-
erally accepted that a response to platinum and the pla-
tinum-free interval (PFI) of relapse, are the determining
clinical surrogates for response and prognosis of recur-
rent OC [5,6]. Platinum-sensitive disease is generally
defined as disease relapsing ≥ 12 months post previous
platinum-based chemotherapy, while relapse within 6-12
months is considered to be partially platinum-sensitive
For patients with platinum-sensitivity re-treatment with
platinum is considered to be the preferred option with
an overall probability of response of around 30% [7,8].
Recent randomized phase III studies have shown that
combinations of platinum with paclitaxel offer signifi-
cant improvements over platinum monotherapies for
platinum-sensitive and partially-sensitive disease. This
applies to both progression-free survival (PFS) and over-
all survival (OS), and was demonstrated in a large
patient population (802 patients) who participated in the
ICON4/AGO-OVAR trial [9]. Most patients had a PFI >
12 months and more than half had received single-agent
platinum as first-line therapy. Neurotoxicity was the
most important limiting adverse event, with 20% of
patients experiencing grade 2-4 neurotoxicity in the
paclitaxel-platinum arm compared to 1% with platinum
monotherapy. Following this, as well as other rando-
mized phase II studies [10], the combination of pacli-
taxel plus platinum (preferably carboplatin) has emerged
as the standard of care for patients with platinum-sensi-
tive OC. However, as neurotoxicity could be a signifi-
cant and persistent problem, re-treatment with the same
regimen may not be feasible because of the cumulative
neurotoxicity of both platinum and paclitaxel. Several
groups are addressing this issue, comparing platinum-
based doublets to platinum. The recent AGO-OVAR 2.5
trial evaluated a carboplatin-gemcitabine combination
over carboplatin in 356 relapsed OC patients with a PFI
of ≥ 6 months, showing that the combination signifi-
cantly improves PFS and responses without worsening
quality-of-life (QoL) [11].
Other agents with single-agent efficacy in second-line
relapsed OC include pegylated liposomal doxorubicin
(LD) and topotecan. Pegylated LD is effective as a
monotherapy in platinum-sensitive and platinum-resis-
tant relapse and shows a similar efficacy to paclitaxel
but with a different toxicity profile [12]. Pegylated LD
was superior to topotecan for PFS and OS with a more
favourable profile in terms of tolerance, cost and QoL
[13]. In recent phase II studies, pegylated LD has
demonstrated significant activity (response rate [RR]
56%) combined with carboplatin [14-16]. Pegylated LD
monotherapy is recommended for platinum-resistant
and partially-platinum sensitive OC patients [7].
T h ea b o v ef o r mt h er a t i o n a l ef o rt h i sr a n d o m i z e d
phase II study, which is designed to evaluate the combi-
nation of carboplatin plus pegylated LD and the stan-
dard carboplatin plus paclitaxel, in patients with OC
relapsing at least 6 months after first-line platinum-
based therapy.
Methods
Eligibility criteria
Women over 18 years old, with a histologically con-
firmed recurrent OC, ≥ 6 months after platinum-based
chemotherapy, entered this study. Patients with bidi-
mensionally measurable disease or only elevated serum
CA-125 (≥ twice the upper limit of normal), with East-
ern Cooperative Oncology Group performance status
(PS) 0-2 and life expectancy of ≥ 3 months were eligible.
Adequate bone marrow, hepatic and renal functions
were required. Patients with a history of malignancy,
other than a completely excised in situ carcinoma of the
cervix or basal carcinoma of the skin, prior or recurrent
central nervous system metastases, serious cardiac dis-
ease, other serious medical illness or an inability to
comply with the treatment plan and follow-up visits
were excluded. Also patients with residual neurotoxicity
from previous platinum and/or taxane chemotherapy
were excluded. The clinical protocol and collateral
translational research studies were approved by the
HeCOG Protocol Review Committee and by the institu-
tional review boards in participating institutions. Writ-
ten informed consent was obtained from all patients
before study entry.
Treatment and dose modifications
Pre-treatment evaluation included a medical history,
physical examination, chest X-ray and abdominal com-
puted tomography scan, electrocardiogram, complete
blood count (CBC), biochemistry and CA-125 determi-
nation. In addition, a baseline neurological examination
was performed and was recommended at every cycle.
Randomization was performed at the central HeCOG
D a t aO f f i c ei nA t h e n s .N os t r atification criteria were
applied at randomisation. The chemotherapy regimens
are depicted in Figure 1. Patients in the control arm (A)
received paclitaxel at 175 mg/m
2 as a 3 h infusion fol-
lowed by carboplatin at an area under the curve (AUC)
5, on day 1. Cycles were repeated every 21 days. Patients
in the experimental arm (B) received pegylated liposo-
mal doxorubicin at 45 mg/m
2 followed by carboplatin at
Bafaloukos et al. BMC Medicine 2010, 8:3
http://www.biomedcentral.com/1741-7015/8/3
Page 2 of 12AUC 5, on day 1. Cycles were repeated every 28 days.
The dose of carboplatin based on AUC was calculated
by the estimated creatinine clearance using Calvert’s for-
mula [17]. All patients received standard premedication
of dexamethasone, dyphenhydramine and ranitidine
prior to paclitaxel, orally 12 h prior to paclitaxel admin-
istration and again intravenously 30 min prior to pacli-
taxel infusion. The same premedication was
administered intravenously only prior to Pegylated LD
infusion for the patients in the carboplatin plus pegy-
lated LD (CLD) arm. Six cycles of chemotherapy were
administered, unless evidence of disease progression or
unacceptable toxicity occurred.
CBC and biochemistry were carried out before each
cycle. CBC was performed routinely only on day1 and
was repeated during cycles only in cases of fever > 38°C,
severe stomatitis or diarrhoea. Chemotherapy was admi-
nistered if absolute neutrophil count (ANC) ≥1.5 × 10
9/
L and platelet count ≥ 100 × 10
9/L. If ANC was < 1.5 ×
10
9/L on day 1, a granulocyte colony-stimulating factor
(G-CSF) was used to speed recovery. A maximum of 2
weeks delay was allowed for toxicity and treatment was
discontinued if longer toxicity-related delays occurred.
In cases of prolonged neutropenia (> 7 days with ANC
<0 . 5×1 0
9/L) despite G-CSF use or febrile neutropenia,
a 25% dose reduction for all drugs was applied addition-
ally to G-CSF. For grade 3 and 4 thrombocytopenia, a
25% and a 50% dose reduction, respectively, was recom-
mended for all drugs. If creatinine clearance was
calculated as < 30 ml/min, treatment was delayed for a
maximum of 2 weeks until recovery; otherwise the
patient was withdrawn from the study. For cardiac
arrhythmia, grade 3 hypersensitivity reactions and any
non-haematological toxicity grade > 2 treatment was
discontinued. Specifically, for grade 2 Palmar-plantar
erythrodysesthesia (PPE), treatment was delayed for a
maximum of 2 weeks until recovery to Grade 0 or 1.
Toxicity criteria were those adopted by the World
Health Organization (WHO). Tumour assessments for
response were performed every two cycles. Patients
receiving at least two cycles of chemotherapy were con-
sidered assessable for a response. Patients receiving at
least one cycle of chemotherapy were assessable for
toxicity. Standard WHO criteria were applied for an
assessment of the response, as these were commonly
used prior to the broad introduction of RECIST
(response evaluation criteria in solid tumours) by our
group and others, and at the time when this study was
initiated. For patients without measurable disease, the
response was determined based on repetitive CA-125
measurements using the algorithm proposed by Rustin
et al. and according to CA-125 Rustin’s criteria [18].
Statistical analysis
This was a randomized phase II study. The principal
endpoint was to evaluate the RR and toxicity of the two
treatment regimens. Secondary endpoints were time-to-
progression (TTP) and OS. The study was performed on
the ‘intent to treat’ basis; thus all eligible patients were
Group A
Group A
R R
A A
N N
D D
O O
M M
I I
Z Z
E E
Paclitaxel  Paclitaxel  175 mg/m 175 mg/m2  2 over 3h over 3h
Carboplatin        Carboplatin        5 AUC 5 AUC
q 3  q 3 wks wks
q  q 4 4 wks wks
Group 
Group B B
Liposomal Doxorubicin 45 Liposomal Doxorubicin 45 mg/m mg/m2 2
Carboplatin        Carboplatin        5 AUC 5 AUC
Figure 1 Treatment schema.
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on the assumption that a 20% difference in response
rate to a baseline of 50% existed between the two
groups. For an alpha and beta error of 0.05 and 0.20,
respectively, 201 patients were needed. Exact binomial
confidence intervals (CI) were used to determine the
95% upper and lower confidence limits of the response
rate. OS was estimated from the initiation of treatment
to the date of last follow-up or until the patient’s death.
TTP was calculated from the initiation of treatment to
the first disease progression. In the calculation of TTP,
deaths due to disease without previous documentation
of progression were considered as events. The Kaplan-
Meier method was used to estimate the time-to-event
distributions. In order to account for potentially impor-
tant prognostic factors, Cox regression analysis was per-
formed for OS and TTP. Performance status (1, 2
versus 0), evidence of disease at study entry (measurable
disease versus elevated marker), age (> 65 years versus ≤
65 years), taxane-containing previous chemotherapy (yes
versus no), PFI (≤ 12 months versus > 12 months) and
randomization group were included in the models. The
backwards selection procedure, using the maximum
likelihood procedure, was used to conclude on the inde-
pendent prognostic factors for OS and TTP. Categorical
variables were compared using Fisher’se x a c tt e s t ,w h i l e
continuous variables were compared using the Mann-
Whitney test. Patient information was collected on stan-
dard HeCOG study forms by authorized HeCOG Data
Managers and entered in the HeCOG Database. The
trial was monitored by certified HeCOG personnel.
Results
Patients’ characteristics
From October 1999 until December 2005, 204 patients
were randomized. Fifteen patients were found to be
non-eligible. The reasons for non-eligibility were: non-
measurable disease (ascites only) without CA125 eleva-
tion (five patients); other cancer (five); no prior plati-
num-based chemotherapy (two); no evidence of disease
at trial initiation (two); and in one case chemotherapy
initiation 20 weeks prior randomization. Data from 189
eligible patients are presented (CP 96, CLD 93). Patients’
characteristics are summarized in Table 1. Most patients
had Performance Status (PS) = 0 (65% in CP, 59% in
CLD). Primary disease characteristics, such as stage at
initial diagnosis, histologic type and grade were balanced
between both groups. Most patients had received only
one previous line of chemotherapy (96% in both
groups), usually containing a taxane (88% in CP, 93% in
CLD). Most patients had a measurable disease, with 7%
in CP and 10% in CLD having elevated CA-125 (≥ twice
t h eu p p e rl i m i to fn o r m a l )a st h eo n l ye v i d e n c eo fd i s -
ease. Most patients had a platinum-free interval (PFI) of
> 12 months (57% in CP, 72% in CLD), with a median
PFI of 14.8 months in CP and 17.3 months in CLD.
Although these values for PFI seemed more favourable
in the CLD group, they did not differ significantly
between the two groups (P = 0.191). The progress of
patients through the various trial stages is shown in our
flow diagram (Figure 2) according to the Consolidated
Standards of Reporting Trials [19].
Treatment characteristics
A total of 503 cycles of CP (median 6, range 1-9) and a
total of 475 cycles of CLD (median 6, range 1-8) were
administered. The median relative dose intensity for
paclitaxel was 0.96 (range 0.66-1.07) and 0.92 (range
0.52-1.09) for pegylated LD, while the median cumula-
tive dose of carboplatin was 2555 (range 370-4800) for
CP and 2400 (range 270-5600) for CLD. Most patients
in both groups completed the planned treatment (68%
in CP and 70% in CLD). The rate of discontinuation
due to toxicity was statistically significantly higher in the
paclitaxel group (13.5% in CP versus 3% in CLD, P =
0.020). Other reasons for non-completion did not differ
significantly between the two groups (CP versus CLD),
and included: disease progression (8% versus 11%);
tumour death (0% versus 3%); voluntary withdrawal (1%
versus 0%); and doctor’s decision (1% versus 1%). Pacli-
taxel dose was reduced in four patients (three due to
haematological toxicity and one due to neurotoxicity),
while pegylated LD dose reduction was performed in 29
patients (20 due to haematological toxicity, seven due to
PPE, two due to stomatitis) (P< 0.001). Defining as a
delay a more than 1 week interval between scheduled
treatment day and actual day of treatment administra-
tion, there were 12 delays in CP (11 due to haematologi-
cal toxicity and one due to hospitalization) and 26
delays in CLD (24 due to haematological toxicity, one
due to GI toxicity and one due to PPE) (P = 0.006).
Toxicity
A total of 177 patients (90 in CP, 89 in CLD) receiving
at least one cycle, were evaluable for the safety analysis.
Toxicity data are available for 173 (89 in CP and 84 in
CLD). The incidence of selected toxicities and suppor-
tive care is summarized in Tables 2 and 3. Haematologi-
cal toxicity was the most common toxicity in both
groups. Grade 3-4 neutropenia did not differ signifi-
cantly between the groups (30% in CP, 35% in CLD),
while severe thrombocytopenia was higher among the
CLD patients (11% in CLD versus 2% in CP, P =0 . 0 1 6 ) .
Febrile neutropenia occurred in nine patients (four in
CP and five in CLD). Few patients discontinued treat-
ment due to haematological events (six due to severe
neutropenia in CP, one due to severe thrombocytopenia
in CLD). There were no toxic deaths. Patients in the
paclitaxel group had significantly more neurotoxicity of
any grade and higher incidence of severe neurotoxicity
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Page 4 of 12Table 1 Selected patient and tumour characteristics.
Total
N = 189
Group A (CP)
N =9 6
Group B (CLD)
N =9 3
Age (years)
Median (range) 63 (37-89) 63 (37-81) 62 (38-89)
Performance status
0 117 (62) 62 (65) 55 (59)
1 57 (30) 27 (28) 30 (32)
2 1 (1) 0 (0) 1 (1)
Unknown 14 (7) 7 (7) 7 (8)
Stage at diagnosis
I 14 (7) 9 (9) 5 (5)
II 16 (9) 9 (9) 7 (8)
III 118 (62) 56 (58) 62 (67)
IV 28 (15) 15 (16) 13 (14)
Unknown 13 (7) 7 (7) 6 (7)
Histologic grade
I 13 (7) 8 (8) 5 (5)
II 57 (30) 27 (28) 30 (32)
III 92 (49) 48 (50) 44 (47)
IV 3 (2) 1 (1) 2 (2)
Unknown 24 (13) 12 (13) 12 (13)
Histologic type
Serous 143 (76) 71 (74) 72 (77)
Mucinous 3 (2) 0 (0) 3 (3)
Endometroid 13 (7) 6 (6) 7 (8)
Clear cell 6 (3) 3 (3) 3 (3)
Other 14 (7) 9 (9) 5 (5)
Unknown 10 (5) 7 (7) 3 (3)
Prior therapy
Surgery 161 (85) 85 (89) 76 (82)
Taxane containing therapy 170 (90) 84 (88) 86 (93)
Number of prior chemotherapy lines
1 181 (96) 92 (96) 89 (96)
> = 2 8 (4) 4 (4) 4 (4)
Sites of disease
Abdominal 95 (50) 49 (51) 46 (50)
Abdominal and pleural effusion or ascites 43 (23) 18 (19) 25 (27)
Extra-abdominal 1 (1) 1 (1) 0 (0)
Both 9 (5) 5 (5) 4 (4)
Ascites or pleural effusion and elevated CA125 14 (7) 10 (10) 4 (4)
Elevated CA 125 as the only evidence of disease 16 (8) 7 (7) 9 (10)
Unknown 11 (6) 6 (6) 5 (5)
Platinum free interval
6-12 months 54 (29) 32 (33) 22 (23)
12.1-24 months 70 (37) 32 (33) 38 (41)
> 24 months 52 (28) 23 (24) 29 (31)
Unknown 13 (7) 9 (9) 4 (4)
Median platinum-free interval (months) 16.5 (6-119) 14.8 (6-96) 17.3 (6-119)
CA 125 at baseline
Median (range) 207 (4-6000) 210 (7-6000) 199 (4-3400)
CP, carboplatin plus paclitaxel; CLD, carboplatin plus pegylated liposomal doxorubicin
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(P = 0.003, grade 3-4 neurotoxicity 7% in CP versus 0%
in CLD, P = 0.029). Five patients in CP discontinued
treatment due to neurotoxicity. Hypersensitivity reac-
tions (HSRs) were more common in CP, mostly grade
1-2 (31% in CP versus 7% in CLD) with two cases of
grade 3 HSR (one in each group). Five patients discon-
tinued treatment because of an HSR (three in CP and
two in CLD). There was only one reported case of HSR
due to carboplatin in a patient receiving CP. All other
reported cases of HSRs were due to paclitaxel or pegy-
lated LD. Alopecia was significantly more common for
patients receiving paclitaxel (grade 2 alopecia 63% in CP
versus 6% in CLD, grade 3 alopecia 20% in CP versus
5% in CLD, P = 0.003). Incidence of PPE and skin toxi-
city was higher in CLD (grade 1-2 38% versus 9% in CP,
P = 0.003) with only one patient developing grade 3
prolonged skin toxicity, because of which treatment was
discontinued. There were no significant differences in
the rates of hospitalization, antibiotic or G-CSF use
between the groups, however, the rate of red blood cell
transfusion was higher in CLD (3% in CP versus 14% in
CLD, P = 0.015).
Efficacy
There were 33 Complete Responders (CRs) (34%; 95%
CI 25%-45%) and 23 Partial Responders (PRs) (24%; 95%
CI 16%-34%) in CP, for an overall response rate (ORR)
57% (95% CI 47%-67%). In CLD there were 21 CRs
(23%; 95% CI 15%-32%) and 26 PRs (28%; 95% CI 19%-
38%), with a 51% ORR (95% CI 40%-61%).) The differ-
ence was not statistically significant. Similarly, when
response rates were analysed for measurable disease and
only CA125 elevated, there were no statistically signifi-
cant differences between the groups (Table 4). Median
follow-up was 43.6 months (95% CI 0.1-74.8), median
TTP was 10.8 months (95% CI 9.2-12.4) in CP and 11.8
RANDOMIZATION 
Randomized n=204 
Eligible n=189 
Carboplatin-Paclitaxel (CP) 
Allocated to intervention: n=96 
Received allocated intervention: n=89 
Did not receive allocated intervention or 
unknown intervention: n=7 
Reasons: Received Carbo- Caelyx: n=2 
               Lost medical record: n=5 
Discontinued intervention: n=24 
Reasons: Non-fatal toxicity: n=13 
               Disease progression: n=8 
               Other: n=3 
Carboplatin-Pegylated LD (CLD) 
Allocated to intervention: n=93 
Received allocated intervention: n=85 
Did not receive allocated intervention or 
unknown intervention: n=8 
Reasons: Never starters: n=1 
     Received Carbo-Taxol: n=1 
               Lost medical record: n=6 
Intention to treat analysis: n=96 
Safety assessment: n=90 
Intention to treat analysis: n=93 
Safety assessment: n=87 
Discontinued intervention: n=20 
Reasons: Death: n=3 
               Non-fatal toxicity: n=3 
               Disease progression: n=10 
               Other: n=4 
Lost to follow up n=8 
Dead n=58 
Still on follow up n=37   
Lost to follow up n=5 
Dead n=64 
Still on follow up n=32 
Figure 2 Progress through the various stages of the trial.
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Page 6 of 12months (95% CI 11.2-12.3) in CLD, with no statistical
difference (P = 0.904). Finally, OS did not differ signifi-
cantly between the groups, reaching 29.4 months (95%
CI 21.9-36.9) in CP and 24.7 months (95% CI 21.0-28.3)
in CLD (p = 0.454) (Figure 3).
Prognostic factors
Employing the Cox proportional hazards model, a uni-
variate and multivariate analysis was performed in order
to assess the effect of pre-specified prognostic factors on
patients’ survival (Table 5). Overall, PS = 0 and longer
PFI (> 12 months) were important independent prog-
nostic factors for survival in this patient population. PFI
was an important independent prognostic factor (PFI
12.1-24 months, P = 0.013 in univariate and P =0 . 0 0 9
in multivariate analysis; PFI > 24 months, P< 0.001 both
in uni- and multi-variate analysis). Performance status
(PS) was also an important prognostic factor, with PS =
0 being significantly better than PS 1-2 (P =0 . 0 0 1i n
uni- and P = 0.003 in multi-variate analysis).
Post-progression therapy
A total of 159 relapses (or disease progressions) were
recorded (81 in CP and 78 in CLD). Detailed informa-
tion on post-progression therapy was available for most
patients: 122 patients received further chemotherapy (61
in CP, 61 in CLD), 29 patients did not receive post-pro-
gression therapy (16 in CP and 13 in CLD) and informa-
tion was not available for eight patients (four in CP and
four in CLD). No details on possible surgical treatment
on relapse were available. Twenty-four patients (39%) in
CP versus 21 (34%) in CLD received a platinum combi-
nation again. One patient in CP received paclitaxel
again versus nine in CLD, while docetaxel was adminis-
tered in five patients in CP and seven in CLD (9% in CP
versus 26% in CLD received taxane again). A total of 26
patients (42%) in CP received pegylated LD as post-pro-
gression treatment versus four patients (6%) in CLD
who received LD again.
Discussion
The combination of carboplatin-paclitaxel is a global
standard following recent consensus recommendations
[20,4]. Although this treatment is highly effective, most
patients recur. The majority are platinum-sensitive at
first relapse, thus, candidates for re-treatment with plati-
num. Indeed, these patients will be generally re-treated
Table 2 Toxicity and supportive care - incidence of severe toxicity among treated patients.
Group A (CP)
N =8 9
Group B (CLD)
N =8 4
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Neutropenia 14 (16) 20 (22) 18 (20) 9 (10) 13 (15) 20 (24) 23 (27) 7 (8)
Anaemia 29 (33) 0 (0) 3 (3) 0 (0) 27 (32) 23 (27) 7 (8) 1 (1)
Leucopenia 24 (27) 23 (26) 5 (6) 1 (1) 25 (30) 30 4 (5) 1 (1)
Thrombocytopenia† 1 (1) 6 (7) 2 (2) 0 (0) 4 (5) 7 (8) 9 (10) 1 (1)
Stomatitis 1 (1) 0 (0) 7 (8) 5 (6) 3 (3) 0 (0)
Nausea/vomiting 18 (20) 10 (11) 1 (1) 0 (0) 16 (19) 12 (14) 4 (5) 0 (0)
Diarrhoea 5 (6) 1 (1) 1 (1) 0 (0) 5 (6) 1 (1) 0 (0) 0 (0)
Infection 1 (1) 3 (3) 0 (0) 3 (4) 1 81) 1 (1) 1 (1)
Neurotoxicity‡ 24 (27) 27 (30) 5 (6) 1 (1) 19 (12) 1 (1) 0 (0) 0 (0)
Alopecia‡ 1 (1) 56 (63) 18 (20) 0 (0) 12 (14) 5 (6) 4 (5) 0 (0)
Allergy 18 (20) 9 (10) 1 (1) 0 (0) 4 (5) 2 (2) 1 (1) 0 (0)
Skin 6 (7) 2 (2) 0 (0) 0 (0) 9 (11) 12 (14) 1 (1) 0 (0)
Hand and foot 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 8 (10) 0 (0) 0 (0)
Fatigue 12 (13) 6 (7) 0 (0) 0 (0) 8 (10) 6 (7) 0 (0) 0 (0)
Fever 5 (6) 0 (0) 0 (0) 2 (2) 4 (5) 0 (0) 0 (0)
Anorexia 4 (4) 2 (2) 0 (0) 0 (0) 5 (6) 0 (0) 0 (0)
Cardiac 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0)
Arthralgias/myalgias 18 (20) 8 (9) 0 (0) 0 (0) 6 (7) 0 (0) 0 (0) 0 (0)
†Rate of severe thrombocytopenia is higher among patients treated with CLD (group B) (11% versus 2%, p = 0.016)
‡Rates of severe neurotoxicity and alopecia are higher among patients treated in group A (CP; 7% versus 0%, P = 0.029 and 20% versus 5%, P = 0.003)
Table 3 Toxicity and supportive care - supportive
treatment.
CP
N =9 0
CLD
N=8 7
Antibiotics 9 (10) 14 (16)
Granulocyte colony-stimulating factor 41 (46) 45 (52)
RBC transfusion † 3 (3) 12 (14)
Platelet transfusion 0 (0) 3 (3)
Hospitalization 11 (12) 13 (15)
† Red blood cell (RBC) transfusion rate is higher among patients treated in
group B (3% in group A versus 14% in group B, P = 0.015)
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light of recent trials showing advantage over platinum
monotherapy [9]. However, the cumulative neurotoxicity
of both drugs, as well as the increased risk of neurotoxi-
city for patients in relapse and the further experience of
alopecia, are essential considerations when selecting sec-
ond-line therapy [21]. As treatment at relapse is rarely
curative, toxicity, tolerance, ease of administration and
QoL should be interrelated to efficacy and survival pro-
longation when novel platinum-based combinations are
evaluated for patients with platinum-sensitive OC.
This study was originally designed in 1999, in an era
when information was totally lacking regarding the ideal
regimen for platinum-sensitive recurrent OC. This is
still a question that has not been clearly and conclu-
sively answered today. The large ICON-4 study (pacli-
taxel-platinum versus platinum) was then ongoing and
was published in 2003. Therefore, both groups in this
study were ‘experimental’ a tt h et i m eo fd e s i g n ,w i t h
preliminary evidence for the one that proved to be the
standard (paclitaxel-platinum). At the time it was
decided to conduct a randomized phase II study, antici-
pating the accrual, and also to investigate whether either
of the two regimens would be worth exploring further
in larger studies [22]. We present the results of this eva-
luation of pegylated LD plus carboplatin and the stan-
dard combination of paclitaxel plus carboplatin in
platinum-sensitive OC patients. This study, with the
limitations of a randomized phase II design, demon-
strates that the combination of pegylated LD plus carbo-
platin as second-line treatment of platinum-sensitive OC
patients is feasible, well-tolerated and effective and
shows a different toxicity profile, with significantly less
neurotoxicity and alopecia than the standard regimen of
paclitaxel plus carboplatin.
Pegylated LD is a unique formulation of doxorubicin,
where encapsulation in liposomes confers different phar-
macokinetic characteristics and a more favourable toxi-
city profile compared to conventional doxorubicin [23].
In phase II and III second-line monotherapy studies,
pegylated LD is equally effective to paclitaxel and super-
ior to topotecan, regardless of platinum sensitivity
[12,13]. A dose of 40 mg/m
2 every 28 days seems the
most commonly utilized in clinical practice today, being
effective and well tolerated in patients with advanced
ovarian cancer [24]. In recent phase II studies different
schedules and dosage regimens of pegylated LD plus
carboplatin have been assessed [14-16]. In most pub-
lished studies the pegylated LD dose is lower than the
one used in our study, ranging from 30-40 mg/m
2 pegy-
lated LD combined with carboplatin AUC 5-6, adminis-
tered every 28 days, excepti nt h eM I T O - 2f i r s t - l i n e
study were carboplatin AUC 5 was combined with pegy-
lated LD 30 mg/m
2 and was administered every 21 days
[25,26]. The dose of 45 mg/m
2 in our study is higher.
Information regarding the optimal dose of pegylated LD
in combinations and, in particular with carboplatin was
limited at the time of initiation of our study and
included data from phase I and II studies, were the dose
of pegylated LD ranged from 30 - 50 mg/m
2 every 4
weeks (dose intensity, 10-12.5 mg/m
2 weekly) combined
with carboplatin AUC5 [26], while the licenced dose for
pegylated LD as monotherapy was 50 mg/m
2 every 4
weeks. We chose the dose of 45 mg/m
2 every 4 weeks
in an attempt to maintain reasonable dose intensity
based on available information at the time. Today it is
known from retrospective analyses and prospective stu-
dies that the lower dose intensity can achieve equally
effective results with better tolerance [26]. The higher
dose utilized in our study was well tolerated in our
Table 4 Response
All patients Measurable disease at trial initiation Elevated CA125
Group A
N= 96
Group B
N =9 3
Group A
N= 79
Group B
N =8 0
Group A
N= 17
Group B
N =1 3
CR 33 (34) 21 (23) 24 (30) 17 (21) 9 (53) 4 (31)
PR 23 (24) 26 (28) 22 (28) 24 (30) 1 (6) 2 (15)
OR 55 (57) 47 (51) 46 (58) 41 (51) 10 (59) 6 (46)
SD 16 (17) 15 (16) 15 (19) 14 (18) 1 (6) 1 (8)
PD 9 (9) 10 (11) 7 (9) 8 (10) 2 (12) 2 (15)
Early Tumor death 0 (0) 3 (3) 0 (0) 3 (4) 0 (0) 0 (0)
Treatment discontinuation prior to evaluation 4 (4) 6 (6) 2 (3) 6 (8) 2 (12) 0 (0)
NA* 17 (18) 6 (6) 9 (11) 8 (10) 2 (12) 4 (31)
*NA (not assessed): in case of measurable disease no computed tomography scans after treatment; in case of CA125 elevation no CA125 value after treatment.
There were no significant differences in any of the rates between the two groups; more specifically, the rates of CR (complete response), PR (partial responbse)
and OR (overall response) were as follows:
All patients: (P = 0.072, 0.619 and 0.309, respectively).
Patients with measurable disease: (P = 0.208, 0.861 and 0.427, respectively).
Patients with evaluable disease (elevated CA125 and/or effusions): (P = 0.283, 0.565 and 0.713, respectively)
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Figure 3 Kaplan-Meier curves for (A) overall survival, (B) time to progression. The blue line corresponds to group A, while the red line to
group B.
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Page 9 of 12patients and haematological toxicity was similar to, or
even lower than, other reports such as the recently pre-
sented rates of neutropenia in the CALYPSO trial where
an even lower dose of CLD was used (30 mg/m
2 every 4
weeks) [27,28]. This inconsistency could possibly be
explained by the fact that blood counts were only routi-
nely performed at day 1 in our study and only in cases
of fever > 38°C during cycles. Therefore, neutropenic
events might have been missed, resulting in some
underestimation of haematological toxicity. Further-
more, we note that, as per study protocol, if ANC was <
1.5 × 10
9/L on day 1, GCSF was administered in order
to speed recovery. The above might also explain the
relatively low rate of grade 4 neutropenia in our study
(10%) and the apparent discrepancy with the rate of
GCSF used (50%). Rates of severe anaemia and fatigue
were also somewhat lower than previously reported,
although anaemia of any grade was more common in
the CLD arm and transfusion rates were significantly
higher in the CLD arm; information on erythropoietin
use was not available.
Expectedly, the only non-haematological toxicity
higher in the CLD arm was skin toxicity and PPE. This
was, however, mostly mild to moderate, resolving with
short treatment delays and only in one case grade 3
toxicity caused treatment discontinuation. On the other
hand the paclitaxel-carboplatin combination induced
significantly higher rates of neurotoxicity causing treat-
ment discontinuation in five cases, while alopecia and
hypersensitivity reactions were also significantly more
common in CP. Similarly, the rates of hypersensitivity
reactions in the CALYPSO trial reported recently at
ASCO 2009 [28], were significantly higher in the CP
arm (18% versus 5%). However, noticeably higher rates
of HSRs related to carboplatin were reported in the
CALYPSO trial, again in the CP group (10% grade 2, 9%
grade 3). In our study only in one case the hypersensi-
tivity reaction was due to carboplatin (in a CP patient);
in all other reported cases the HSR was due to either
paclitaxel in the CP group or pegylated LD in the CLD
group. We utilized standard premedication in both
groups (orally [12 h] and intravenously [30 min] prior
to paclitaxel infusion, 30 min intravenously prior to
pegylated LD infusion). It is also important to note that
overall the rate of discontinuation due to toxicity was
significantly higher in the paclitaxel group (13.5% versus
3%, P = 0.016), as was seen in the CALYPSO results
(toxicity-related early treatment discontinuation in CP
15% versus 7% in CD) [28]. With regards to neurotoxi-
city, the rate of grade 2-4 neurotoxicity seen in our
study (37%) with CP was higher than that reported in
the ICON4 trial (20%) [9]. This could be explained by
the fact that most patients in our study had previously
received a platinum-taxane combination (90% total, 88%
in CP), while in the ICON4 more than half (57%) had
not received a taxane at first-line treatment. We, there-
fore, believe that our study reflects the problem of neu-
rotoxicity more accurately in the context of the recent
Table 5 Prognostic factors. Cox regression analysis for patients’ survival.
Univariate Multivariate
HR 95% CI P HR 95% CI P
Age
<=6 5 1 - -
> 65 0.83 0.57-1.21 0.329
Performance status
01 - - 1 - -
1-2 1.96 1.32-2.90 0.001 1.89 1.25-2.88 0.003
Previous exposure to taxanes
No 1 - -
Yes 1.18 0.62-2.27 0.610
Disease status
Non-measurable 1 - -
Measurable 1.49 0.88-2.55 0.141
Platinum-free interval
6-12 months 1 - - 1 - -
12.1-24 months 0.58 0.37-0.89 0.013 0.54 0.34-0.86 0.009
> 24 months 0.37 0.22-0.61 < 0.001 0.36 0.21-0.61 < 0.001
Randomization group
A1 - - 1 - -
B 1.15 0.78-1.66 0.455 1.19 0.80-1.76 0.399
CI, confidence interval; HR, (Hazard Ratio)
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Page 10 of 12changes of first-line treatment in ovarian cancer. Simi-
larly, the CALYPSO trial included patients pretreated
with both a platinum and a taxane, as this is nowadays
common practice in most parts of the world in first-line
treatment of advanced ovarian cancer. In their recently
presented results, the CALYPSO investigators showed a
significantly higher severe neuropathy rate in the CP
arm (27% versus 4%) and concluded that the combina-
tion of PLD-carboplatin was well tolerated with lower
rates of severe and long-lasting (neuropathy) toxicities
[28]. Although QoL measurements were not undertaken
i no u rs t u d y ,t h eC L Dt o x i c i t yp r o f i l e ,w i t hl e s sn e u r o -
toxicity and alopecia, seems more favourable. However,
this should be conclusively investigated in larger rando-
mized studies that incorporate patient perception mea-
surements. Such QoL measurements were undertaken in
the large CALYPSO trial, the results, however, have not
yet been presented.
Our study was not powered to detect differences in
survival; therefore, data on TTP and OS are only indica-
tive. The observed response rates in our study, as well
as our data on TTP and OS are comparable to those
reported in the two large randomized phase III trials on
platinum-sensitive disease [9,11]. They come to further
underline the efficacy of platinum-based combinations
in a population characterized (65% of patients) of predo-
minantly long PFI (> 12 months). Additionally, in accor-
dance to previous evidence, our data demonstrated that
longer PFI and better PS are significant independent
prognostic factors for survival [7]. The above compare
favourably with recently presented results both in first-
and second-line treatment of advanced OC patients: the
MITO-2 study, a large randomized comparison of CP
versus CLD as first-line treatment showed equal
response rate and favourable toxicity profile for the
pegylated LD combination compared to the standard
paclitaxel combination while PFS analysis is still pending
[29]. Furthermore, the CALYPSO trial in the second-line
setting as our study is, showed significant superiority of
the pegylated LD combination in terms of tolerance and
PFS (18% reduction in risk of recurrence; HSR 0.82; P =
0.005) [28].
Conclusions
Our data support the clinical efficacy and tolerability of
pegylated LD combined with carboplatin for the second-
line treatment of platinum-sensitive OC patients. The
CALYPSO phase III study evaluated a similar combina-
tion of CLD versus CP, using lower dose intensity for
pegylated LD. The recently presented results of this
large multinational study come to strengthen, with ran-
domized evidence, the previous indications of a more
favourable toxicity profile of pegylated LD combined
with carboplatin compared to a paclitaxel combination
[24] in the second-line setting. The results of our study,
regarding the safety and toxicity of the CLD combina-
tion, are consistent with and add to the evidence of the
CALYPSO trial. The combination of pegylated LD plus
carboplatin has satisfactory activity and shows a differ-
ent toxicity profile to the standard combination of pacli-
taxel-carboplatin, with significantly less neuropathy and
alopecia, worthy of further evaluation and use as an
alternative evidence-based treatment option for patients
with platinum-sensitive OC.
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